Oxea GmbH

EANS-News: Oxea GmbH
Oxea reports stable Q3 results

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
quarterly report

Luxembourg (euro adhoc) - Highlights Q3 2012:

* Net sales were EUR365 million versus EUR383 million in the prior year period
* Gross profit was EUR48 million versus EUR48 million in the prior year period
* Operating profit was EUR40 million versus EUR44 in the prior year period
* Net income was EUR17 million versus EUR22 million in the prior year period
* Adjusted EBITDA was EUR46 million versus EUR49 million in the prior year

Oxea, a leading global supplier of Oxo Intermediates and Oxo Derivatives, today
announced for the third quarter of 2012 continued stable results with an
adjusted EBITDA of EUR46 million after EUR46 million in Q2 2012 and EUR45
million in Q1 2012. Considering the general summer seasonality in the Northern
hemisphere and the continued soft world economy, this stable earnings
development on a quarter to quarter basis repeatedly underpins the robustness of
Oxea's business model. Compared to the corresponding period of the prior year,
adjusted EBITDA was moderately impacted, with a drop of 6% as a result of the
overall weak macroeconomic demand and its impact on the global manufacturing
industry. In the nine months of 2012, Oxea generated strong cash flows, mainly
due to a significant improvement of Trade Working Capital. Cash provided by
operating activities was EUR82 million compared with EUR78 million in the
corresponding period of the prior year. The strong financial position allowed
Oxea to complete the third optional redemption of 5% of the outstanding Senior
Secured Notes in August 2012. Within two years after the Bond issue, Oxea has
executed all three redemption options, each of 5% of outstanding Senior Secured
Notes at a redemption price of 103% as permitted under the terms and conditions
of the Indenture. During the first nine months Oxea invested EUR60 million into
its business largely driven by the implementation of the strategic growth
projects, leading to a further shift to high margin downstream derivatives
within the product portfolio. The second production facility for the
manufacturing of specialty esters in Oberhausen has been mechanically completed
at the end of October. The third production plant for carboxylic acids in
Oberhausen is currently being finalized and expected to be completed during Q1

                      Three months      Nine months  
  In EUR million         ended            ended      
  Unaudited           September 30     September 30  
                      2012    2011    2012     2011  
 Net sales           364.9   382.8  1,116.1  1,150.9 
 Gross profit         47.7    48.5    141.4    171.5 
 SG&A                 (9.2)   (8.4)   (28.4)   (27.6)
 R&D                  (1.7)   (1.6)    (5.0)    (4.6)
 Other operating       3.0     5.4     16.8      8.5 
 Operating profit     39.8    43.9    124.8    147.8 
 Net income           16.6    21.9     55.4     68.3 
 Adjusted EBITDA      45.7    48.6    136.3    170.7 

Net sales
Net sales for the three months ended September 30, 2012 were EUR364.9 million, a
decrease of 4.7% compared with the corresponding period of the prior year.
Overall, volumes were in line with the Q3 2011. Oxo Intermediates volumes were
in line with the corresponding period of the prior year and Oxo Derivatives
volumes traded 3.2% higher. Of our revenues for the three months ended September
30, 2012, EUR162 million resulted from sales in Europe, EUR120 million in North
America, and EUR83 million in the rest of the world compared to EUR176 million,
EUR120 million, and EUR87 million, respectively, in the prior year period.

Gross profit
Gross profit for the three months ended September 30, 2012 amounted to EUR47.7
million and traded essentially in line with the corresponding period of the
prior year. 

Selling, general & administration expense (SG&A)
SG&A expense for the three months ended September 30, 2012 amounted to EUR9.2
million compared with EUR8.4 million in the corresponding period of the prior
year, mainly due to higher consulting fees and personnel costs.

Other operating income/(expense)
Net other operating income for the three months ended September 30, 2012
amounted to EUR3.0 million compared with a net other operating income of EUR5.4
million in the corresponding period of the prior year. The decrease is primarily
attributable to lower insurance income.

Operating profit
Operating profit for the three months ended September, 2012 was EUR39.8 million
compared with EUR43.9 million in the corresponding prior year period, primarily
as a result of higher SG&A expense and lower other income as explained above.

Financial result 
Net financial expense was EUR14.4 million compared with EUR10.8 million in Q3
2011 mainly due to the premium paid for the optional bond redemption in August
2012 and net foreign currency gains in the corresponding period of the prior

Net income
Net income was EUR16.6 million compared with EUR21.9 million in the
corresponding period of the prior year due to higher SG&A expense, lower other
income and lower net foreign currency gains partly compensated by lower income

Adjusted EBITDA
Adjusted EBITDA at EUR45.7 million compared with EUR48.6 million in the
corresponding period of the prior year was mainly driven by higher SG&A expense
and lower other income.

Cash flow
The company continued to generate positive free cash flow and during the first
nine months of 2012, Oxea generated EUR82.4 million in cash from operating
activities compared with EUR78.1 million in the corresponding period of the
prior year. Higher inflows from working capital were partly offset by lower
earnings from operating activities and higher income tax payments. 

Cash used in investing activities was EUR60.2 million compared with EUR21.6
million in the corresponding period of the prior year due to higher spending for
growth projects. 

Cash used in financing activities was EUR94.4 million compared to EUR130.4
million in the corresponding period of the prior year, which included a payment
to shareholders in the amount of EUR55 million. 

Oxea is a global manufacturer of Oxo Intermediates and Derivatives such as
alcohols, polyols, carboxylic acids, specialty esters and amines. These products
are sold in the merchant market (where sales are to third party customers) and
used for the production of high-quality coatings, lubricants, cosmetic and
pharmaceutical products, flavourings and fragrances, printing inks and plastics.
In 2011, Oxea generated revenue of about EUR1.5 billion with its 1,365 employees
in Europe, the Americas and Asia.

Please note: 

This press release contains financial information regarding the businesses and
assets of OXEA S.à r.l. (the "Company") and its consolidated subsidiaries (the
"Group"). Such financial information has not been audited, reviewed or verified
by any independent accounting firm. The inclusion of such financial information
in this press release or any related presentation should not be regarded as a
representation or warranty by the Company, any of its respective affiliates,
advisors or representatives or any other person as to the accuracy or
completeness of such information's portrayal of the financial condition or
results of operations by the Group.

This press release and related presentations (including on our website) may
contain information, data and predictions about our markets and our competitive
position. While we believe this data to be reliable, it has not been
independently verified, and we make no representation or warranty as to the
accuracy or completeness of such information set forth in this document.
Additionally, industry publications and reports from which such information,
data or predictions may be obtained generally state that the information
contained therein has been obtained from sources believed to be reliable but
that the accuracy and completeness of such information is not guaranteed and in
some instances state that they do not assume liability for such information. We
cannot therefore assure you of the accuracy and completeness of such information
and we have not independently verified such information. In addition, we have
made statements in this document regarding our industry and position in the
industry based on our experience and our own investigation of market conditions.
We cannot assure you that the assumptions underlying these statements are
accurate or correctly reflect the state and development of, or our position in,
the industry, and none of our internal surveys or information has been verified
by any independent sources.

Certain statements in this document are forward-looking. By their nature,
forward-looking statements involve known and unknown risks and uncertainties
because they relate to events and depend on circumstances that may or may not
occur in the future. Forward-looking statements are not guarantees of future
performance. These factors include, among others: the cyclical and highly
variable nature of our business and its sensitivity to changes in supply and
demand; adverse and uncertain global economic conditions; the highly variable
nature of raw materials costs and any loss of key suppliers or supply shortages
or disruptions; the competitive nature of our industry; the ability to comply
with current or future laws and regulations relating to environmental, health
and safety matters as well as the safety of our products, related costs of
maintaining compliance and addressing liabilities as well as risks relating to
compliance with antitrust and tax laws; our reliance on a limited number of
suppliers for certain of our key raw materials; operational risks, including the
risk of environmental contamination and potential product liability claims;
operational interruptions at our facilities due to events that are outside of
our control such as severe weather conditions, unscheduled downtimes, terrorist
attacks, natural disasters or other events that may interrupt or damage our
operations or the impact of scheduled outages on our results of operations; the
risk that our insurance coverage may not be sufficient to cover all risks; risks
relating to the global nature of our operations, including, among others,
fluctuations in exchange rates; the loss of major customers or key customers for
certain of our products; the loss of key personnel; risks relating to
acquisitions and dispositions, including any impairment risks with respect to
historical acquisitions, our ability to successfully integrate acquired
businesses, and unexpected liabilities relating to such acquisitions or
contingent liabilities in connection with such dispositions; the requirement to
make further contributions to our pension schemes; the failure to protect our
intellectual property rights; limitations on our ability to adjust the quality
of certain products that we manufacture; and potential conflicts of interests
with our principal shareholder.

These and other factors could adversely affect the outcome and financial effects
of the plans and events described herein. Forward-looking statements contained
in this document regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the future. New
risks can emerge from time to time, and it is not possible for us to predict all
such risks, nor can we assess the impact of all such risks on our business or
the extent to which any risks, or combination of risks and other factors, may
cause actual results to differ materially from those contained in any
forward-looking statements. Neither the Company nor the Group undertakes any
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. You should not place
undue reliance on forward-looking statements, which speak only as of the date of
this document.

EBITDA is defined as net income for the year before financial result, income
taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA
adjusted to remove the effects of certain non-cash and non-recurring expenses
and charges. EBITDA and Adjusted EBITDA are supplemental measures of our
performance and liquidity that are not required by or presented in accordance
with IFRS. EBITDA and Adjusted EBITDA are not measurements of our financial
performance or liquidity under IFRS and should not be considered as an
alternative to profit for the period presented, results from operating
activities or any other performance measures derived in accordance with IFRS or
as an alternative to cash flow from operating activities as a measure of our
liquidity. We believe EBITDA and Adjusted EBITDA facilitate operating
performance comparisons from period to period and company to company by
eliminating potential differences caused by variations in capital structures
(affecting interest expense), tax positions (such as the impact on periods or
companies of change in effective tax rates or net operating losses) and the age
and book value and amortization of tangible and intangible assets (which have an
effect on related depreciation expense). We also present EBITDA and Adjusted
EBITDA because we believe it these are frequently used by securities analysts,
investors and other interested parties in the evaluation of similar issuers, the
majority of which present EBITDA and Adjusted EBITDA when reporting their
results. Finally, we present EBITDA and Adjusted EBITDA as measures of our
ability to service our debt.

Further inquiry note:

Bernhard Spetsmann
Managing Director (Finance, IT)

Birgit Reichel

end of announcement                               euro adhoc 

company:     Oxea GmbH
             Otto-Roelen-Straße 3
             D-46147 Oberhausen
phone:       +49(0)208 693 3112
FAX:         +49(0)208 693 3101
mail:     birgit.reichel@oxea-chemicals.com
WWW:      http://www.oxea-chemicals.com
sector:      Chemicals
ISIN:        XS0523636594
stockmarkets: Open Market: Frankfurt 
language:   English

Weitere Meldungen: Oxea GmbH

Das könnte Sie auch interessieren: